Real-World Experience of Immune-Checkpoint Inhibitors in Older Patients with Advanced Cutaneous Squamous Cell Carcinoma
ConclusionsICIs have demonstrated efficacy and have an acceptable safety profile among older patients with advanced CSCC, with comparable efficacy to what has been demonstrated in current clinical trials.
Source: Drugs and Aging - Category: Geriatrics Source Type: research
More News: Cancer & Oncology | Carcinoma | Chemotherapy | Clinical Trials | Geriatrics | Immunotherapy | Skin Cancer | Squamous Cell Carcinoma | Toxicology